Ovoca Bio plc, a bio-technology company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions.
Adequate balance sheet and overvalued.
Share Price & News
How has Ovoca Bio's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OVXA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: OVXA exceeded the Irish Pharmaceuticals industry which returned 16.9% over the past year.
Return vs Market: OVXA exceeded the Irish Market which returned 5.3% over the past year.
Price Volatility Vs. Market
How volatile is Ovoca Bio's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWhat Kind Of Shareholders Own Ovoca Bio plc (ISE:OVXA)?
4 months ago | Simply Wall StHere's Why We're A Bit Worried About Ovoca Bio's (ISE:OVXA) Cash Burn Situation
6 months ago | Simply Wall StDo Institutions Own Ovoca Bio plc (ISE:OVXA) Shares?
Is Ovoca Bio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OVXA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OVXA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OVXA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: OVXA is unprofitable, so we can't compare its PE Ratio to the Irish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OVXA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OVXA is good value based on its PB Ratio (0.5x) compared to the XE Pharmaceuticals industry average (3.2x).
How is Ovoca Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ovoca Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Ovoca Bio's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Ovoca Bio competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Ovoca Bio performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OVXA is currently unprofitable.
Growing Profit Margin: OVXA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OVXA is unprofitable, but has reduced losses over the past 5 years at a rate of 49.6% per year.
Accelerating Growth: Unable to compare OVXA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OVXA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.5%).
Return on Equity
High ROE: OVXA has a negative Return on Equity (-9.24%), as it is currently unprofitable.
How is Ovoca Bio's financial position?
Financial Position Analysis
Short Term Liabilities: OVXA's short term assets (€3.5M) exceed its short term liabilities (€122.0K).
Long Term Liabilities: OVXA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: OVXA is debt free.
Reducing Debt: OVXA had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if OVXA has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OVXA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Ovoca Bio's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OVXA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OVXA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OVXA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OVXA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OVXA's dividend in 3 years as they are not forecast to pay a notable one for the Irish market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Kirill Golovanov (41yo)
Mr. Kirill Golovanov has been the Chief Executive Officer at Ovoca Bio plc (formerly known as Ovoca Gold plc) since May 2012. Mr. Golovanov has been Corporate Secretary of Ovoca Bio plc (formerly known as ...
CEO Compensation Analysis
Compensation vs Market: Kirill's total compensation ($USD0.00) is below average for companies of similar size in the Irish market ($USD325.59K).
Compensation vs Earnings: Kirill's compensation has been consistent with company performance over the past year.
|Executive Chairman||12.42yrs||€106.00k||no data|
|CEO, Company Secretary & Executive Director||8.08yrs||€164.00k||23.92% €2.7m|
|Interim Chief Business Officer & Non-Executive Director||1.92yrs||no data||no data|
|Non-Executive Director||14yrs||€106.00k||14.29% €1.6m|
|Independent Non-Executive Director||11.42yrs||€16.00k||no data|
|Non-Executive Director||1.92yrs||no data||no data|
Experienced Board: OVXA's board of directors are considered experienced (9.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ovoca Bio plc's company bio, employee growth, exchange listings and data sources
- Name: Ovoca Bio plc
- Ticker: OVXA
- Exchange: ISE
- Founded: 1985
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €11.256m
- Shares outstanding: 81.56m
- Website: https://ovocabio.com
Number of Employees
- Ovoca Bio plc
- 17 Pembroke Street Upper
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OVXA||ISE (Irish Stock Exchange)||Yes||Ordinary Shares||IE||EUR||Jan 1992|
|OVB||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Jan 1992|
|OVXA||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jan 1992|
Ovoca Bio plc, a bio-technology company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing Libicore, a medication for treatment of female sexual dysfunction. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was founded in 1985 and is based in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/05 20:55|
|End of Day Share Price||2020/06/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.